Compare AEIS & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEIS | GH |
|---|---|---|
| Founded | 1981 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8B | 13.3B |
| IPO Year | 1996 | 2018 |
| Metric | AEIS | GH |
|---|---|---|
| Price | $296.18 | $86.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 19 |
| Target Price | ★ $283.36 | $121.11 |
| AVG Volume (30 Days) | 543.7K | ★ 1.6M |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.13% | N/A |
| EPS Growth | ★ 168.53 | 6.74 |
| EPS | ★ 3.84 | N/A |
| Revenue | $453,095,000.00 | ★ $982,021,000.00 |
| Revenue This Year | $21.75 | $33.40 |
| Revenue Next Year | $13.24 | $28.32 |
| P/E Ratio | $80.81 | ★ N/A |
| Revenue Growth | ★ 38.39 | 32.88 |
| 52 Week Low | $75.01 | $36.36 |
| 52 Week High | $360.00 | $120.74 |
| Indicator | AEIS | GH |
|---|---|---|
| Relative Strength Index (RSI) | 44.06 | 42.00 |
| Support Level | $288.91 | $82.26 |
| Resistance Level | $350.00 | $90.28 |
| Average True Range (ATR) | 18.39 | 3.74 |
| MACD | -3.18 | 0.49 |
| Stochastic Oscillator | 2.47 | 51.50 |
Advanced Energy Industries Inc provides precision power conversion, measurement, and control solutions. The company designs, manufactures, sells, and services power electronics conversion products that transform raw electrical power into controllable, usable power for complex equipment. It operates in one reporting segment, Power Electronics Conversion Products, serving the Semiconductor Equipment, Data Center Computing, Industrial and Medical, and Telecom and Networking markets. Its products include Plasma Power Products, AC-DC Power Supply Units, DC-DC Converters, High Voltage solutions, SCR Power Controllers, and Sense and Measurement solutions. The company operates in the United States, Asia, Europe, and other regions.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.